Gill's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • FY 2024
Question
Gill from Needham & Company asked about the durability of Recursion's compute moat given falling costs, requested visibility on 2025 milestone payments, and questioned how the company will measure productivity for its virtual cell initiative.
Answer
CEO Christopher Gibson and CFO Ben Taylor addressed the questions. Gibson stated that compute at their scale remains a 2-3 year moat, but the true long-term advantage is their proprietary data. Taylor declined to give specific 2025 milestone guidance but noted they expect to continue achieving milestones from advancing programs and delivering phenomaps. Gibson added that the virtual cell's productivity will be proven when the company can reduce new data generation and instead focus on validating predictions from the model.